Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 5,060 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Pneumonia, Ventilator Associated Pneumonia
Interventions: Lactobacillus GG, placebo; Dietary Supplement
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Lipoprotein Metabolism, PCSK9, Proteomics
Interventions: control fish oil, LCMUFA-rich saury oil; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dermatitis, Atopic
Interventions: BBI-5000; Drug
Lead sponsor: Fresh Tracks Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Cancer
Interventions: Ipatasertib (capsule), Ipatasertib (tablet); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Asthma
Interventions: Dupilumab, Placebo, Asthma Controller Therapies, Asthma Reliever Therapies; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 18
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 14 more

Conditions: Asthma
Interventions: BI 671800, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Huntington Beach, California • Mission Viejo, California • Stockton, California + 11 more

Conditions: Bariatric Surgery, Cardiac Surgery With Sternotomy, Post-operative Pain
Interventions: Suzetrigine, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 85 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions: Milk thistle (MT), Placebo, Lifestyle Modification, Fibroscan; Drug · Behavioral · Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 9 Years to 22 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
Interventions: Loncastuximab Tesirine, Ibrutinib; Drug
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 12
States / cities: Orange, California • Redlands, California • Miami, Florida + 8 more

Conditions: Overweight and Obesity, Insulin Resistance, Diabetes, Gestational, Hypertension in Pregnancy, Pre-Eclampsia
Interventions: DHA Supplements, Placebo Supplements; Dietary Supplement
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hidradenitis Suppurativa
Interventions: Fecal Microbiota - lyophilized, Placebo drug; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Kidney Failure
Interventions: Kibow Biotics; Dietary Supplement
Lead sponsor: Kibow Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma
Interventions: L-arginine, Placebo; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Chronic Rhinosinusitis
Interventions: Itraconazole, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cystinosis
Interventions: RP103; Drug
Lead sponsor: Amgen; Industry
Eligibility: Up to 6 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Recurrent Glioblastoma Multiforme(GBM)
Interventions: ACT001, ACT001 + Pembrolizumab; Drug
Lead sponsor: Accendatech USA Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hyperlipidemia
Interventions: AEGR-733, placebo, AEGR-733 and atorvastatin, AEGR-733 and fenofibrate, AEGR-733 and ezetimibe; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more

Conditions: Hepatitis C, Chronic
Interventions: Telaprevir and Sofosbuvir; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Sleep Apnea, Elderly Adults
Interventions: Hyperoxia/oxygen, Acetazolamide, Finasteride; Other · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: Durvalumab, Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 7
States / cities: Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more

Conditions: Healthy Volunteers
Interventions: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr), 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL), Omeprazole; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Alzheimer s Disease
Interventions: Terazosin (Hytrin), Placebo; Drug · Other
Lead sponsor: Qiang Zhang; Other
Eligibility: 50 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Basal Cell Carcinoma
Interventions: Vismodegib 150 mg; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 21
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 17 more

Search by objective public record fields.

Lactobacillus GG in the Prophylaxis of Ventilator Associated Pneumonia

Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults

A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Evaluation of Dupilumab in Children With Uncontrolled Asthma

Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery

Milk Thistle Clinical Trial in Pediatric NAFLD

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

DHA Supplements to Improve Insulin Sensitivity in Obese Pregnant Women (The Omega-3 Pregnancy Study)

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

Observational Study of Kibow Biotics in Dialysis Patients

Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma

Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1

Sleep Apnea in Elderly

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Terazosin And Metabolic Engagement in Alzheimer's Disease

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma